Table 1.
Description of the studies included in the analysis and VDR rs2228570 minor allele and genotype frequencies by case-control status
| Study Name | Case Ascertainment |
Selection of controls |
No. participants (participation rate) |
VDR rs2228570 genotype | MAF among controls |
P† | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Invasive Cases |
Controls | No. (%) Cases | No. (%) Controls | |||||||||
| CC | CT | TT | CC | CT | TT | |||||||
| MALOVA22 (Malignant Ovarian Cancer Study, Denmark) |
Incident cases (30–80 years old) diagnosed 1994–1999 from Copenhagen, Frederiksberg, and surrounding counties |
Randomly selected from the general female population within the study area (aged 30–80 years) using the computerized Central Population Register |
424 (79%) |
1183 (67%) |
159 (38) | 208 (49) | 57 (13) | 475 (40) | 545 (46) | 163 (14) | 0.37 | 0.74 |
| SEARCH23 (Studies of Epidemiology and Risk Factors in Cancer Heredity: Ovarian Cancer Study, UK) |
Cases <70 years old from East Anglia, West Midlands, and Trent regions of England; prevalent cases diagnosed 1991–1998; incident cases diagnosed 1998–2004 |
Randomly selected from the EPIC-Norfolk cohort of 25000 individuals aged 45–74 based in the same geographical regions as the cases |
813 (67%) |
1224 (84%) |
296 (36) | 406 (50) | 111 (14) | 484 (40) | 552 (45) | 188 (15) | 0.38 | 0.14 |
| GEOCS24 (Genetic Epidemiology of Ovarian Cancer Study, CA, USA) |
Incident cases (20–64 years old) diagnosed from 1997– 2002 in Greater Bay Area Cancer Registry, San Francisco |
Identified through random-digit dial in the same geographic area as cases |
269 (75%) |
365 (75%) |
104 (39) | 116 (43) | 49 (18) | 146 (40) | 176 (48) | 43 (12) | 0.36 | 0.36 |
| UKOPS25 (United Kingdom Ovarian Cancer Population Study) |
Cases attending ten Major Gynaecological Oncology NHS centers in England, Wales and Northern Ireland from 2006 onwards |
Women aged 50 to 74 from the general population, participating in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. |
258 (86%) |
567 (97%) |
101 (39) | 115 (45) | 42 (16) | 220 (39) | 281 (49) | 66 (12) | 0.36 | 0.10 |
| HAWAII26 (Hawaii Ovarian Cancer Study. Hawaii, USA) |
Incident cases (18–87 years old) diagnosed 1993–2007, ascertained through Hawaii Tumor Registry |
Randomly selected from the participants in the annual survey of representative households that is conducted under statutory provision . |
56 (66%) |
140 (69%) |
13 (23) | 33 (59) | 10 (18) | 57 (41) | 64 (46) | 19 (13) | 0.36 | 0.88 |
| P* | 0.15 | 0.49 | ||||||||||
| All | 1820 | 3479 | 673 (37) | 878 (48) | 269 (15) | 1382 (40) | 1618 (46) | 479 (14) | 0.37 | 0.88 | ||
| Excluding HAW | 1764 | 3339 | 660 (37) | 845 (48) | 259 (15) | 1325 (40) | 1554 (46) | 460 (14) | 0.37 | 0.90 | ||
Abbreviations: MAF, minor allele frequency; EPIC, The European Prospective Investigation of Cancer.
*
P for the log likelihood ratio test assessing heterogeneity of genotype distribution by study.
†
P from the chi-square test assessing deviation of genotype frequencies among controls from those expected under Hardy-Weinberg equilibrium.